NDA 017823 · Sun Pharm Inds INC
Halog
Halcinonide · Topical · Corticosteroid
Last checked: Nov 20, 2026Latest source record: Mar 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1977
May 4, 1977
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
194
59 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2025.
INDICATIONS AND USAGE HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 4, 1977 Original approval · Type 3 - New Dosage Form
1 products under this application
- HALOG · HALCINONIDE 0.1% · SOLUTION, TOPICAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Halcinonide" as an intervention, any sponsor and status, largest first.
Psoriasis Treatment Center of Central New JerseyAcademic, hospital or other
NCT04347473 · 25 participants (planned) · Start Apr 6, 2020 · Primary completion Dec 30, 2020
Drug: Ilumya Injectable Product · For: Psoriasis
Sites: East Windsor, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective23
- psoriasis19
- rash16
- pain13
- pruritus13
- arthralgia12
- diarrhoea10
- headache10
- nausea10
- fatigue9
- off label use9
- condition aggravated7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 15 |
| 2016 | 18 |
| 2017 | 33 |
| 2018 | 17 |
| 2019 | 13 |
| 2020 | 15 |
| 2021 | 15 |
| 2022 | 15 |
| 2023 | 13 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses.
Sudilovsky A, Clewe TH · J Clin Pharmacol 1975 · Clinical Trial, Comparative Study
- Low concentration halcinonide cream in the topical management of atopic dermatitis in pediatric patients.
Rauschkolb EW, Bender SH, Ebling JK, et al. · Cutis 1981 · Clinical Trial, Comparative Study
- The influence of topical steroid application on tuberculin skin reactions in healthy persons.
Thestrup-Pedersen K, Ahlburg H, Hansen P, et al. · Acta Derm Venereol 1982 · Clinical Trial, Randomized Controlled Trial
- Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
Bagel J, Novak K, Nelson E · J Drugs Dermatol 2023 · Clinical Trial
- Influence of the timing of ultrasound application on the penetration of corticosteroids.
Clijsen R, Baeyens JP, Barel AO, et al. · Skin Res Technol 2013 · Randomized Controlled Trial
- A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroid-responsive dermatoses.
Fattah AA, El-Shiemy S, Faris R, et al. · J Int Med Res 1976 · Clinical Trial, Comparative Study
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.